SNOA - CONSENSUS CO - Sonoma Pharmaceuticals

Sonoma Pharmaceuticals (SNOA) relies on recognition from dermatologists and favorable hospital agreements, controlling component costs and patent purity. An efficient network of plants in Europe and the US minimizes transportation costs, maintaining margins at 12.06. Outsourcing packaging and distribution to third-party contractors under strict SLAs reduces risks. This price chart on GURU.Markets clearly demonstrates the dynamics of this business.

This indicator aggregates average expert target valuations, transforming discrete forecasts into a continuous trend of the asset's fundamental value. By analyzing the analyst consensus price target, investors can track the dynamics of market expectations regarding the potential of Sonoma Pharmaceuticals (SNOA) within the wound care segment and the expansion of safe disinfectant solutions across B2B dermatology and dentistry channels.